Fludarabine-related hemolytic anemia in chronic lymphocytic leukemia and lymphoproliferative disorders.
Taha
H M
HM
Narasihman
P
P
Venkatesh
L
L
Cawley
M
M
Kaplan
B
B
D000368:Aged; D000743:Anemia, Hemolytic / Q000139:chemically induced* / Q000188:drug therapy / Q000453:epidemiology; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D017053:Infection Control; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D007166:Immunosuppressive Agents; D014740:Vidarabine; C024352:fludarabine; D011241:Prednisone